Slideshow
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
This slideshow reviews blinatumomab (Blincyto), indicated for Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Table of Contents
Slide 4: Dosage and Administration
Slide 16: Cautions, Effects, and Interactions
Slide 28: What to Tell Your Patient
Slide 36: Reference